KIT and ovarian neoplasm: Our data on the cytotoxicity of suboptimal doses of the treatments on the tumorspheres suggest that combinations of platinum drugs with C-KIT, MAPK, PI3K or DNA-damage inhibitors may be a suitable therapeutic strategy to increase activity, avoid recidiva or the metastasis of platinum-resistant ovarian tumors.